Cover Image
市場調查報告書

多發性硬化症:KOL (關鍵意見領袖) 分析

Multiple Sclerosis: KOL Insight

出版商 FirstWord 商品編碼 344325
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
多發性硬化症:KOL (關鍵意見領袖) 分析 Multiple Sclerosis: KOL Insight
出版日期: 2015年10月01日 內容資訊: 英文
簡介

Roche及Biogen的創新製劑Ocrelizumab正大幅改變多發性硬化症治療的範例。

本報告提供多發性硬化症的已上市藥物及開發中藥物的相關調查、效用、安全性上的課題、患者的影響力等相關資料、美國及歐洲的12名關鍵意見領袖 (KOL) 的各種見解彙整。

調查課題

  • 治療範例的變化
    • Ocrelizumab:初期用RRMS的二線藥物抬頭,不過,預計此後轉移到一線藥物,在PPMS的領域得勢。臨床上的優點和作為現有產品的高效力替代品的理由。
  • 安全性的課題
    • 許多藥物對多發性硬化症有效,不過,伴隨各種副作用。對安全處方的影響和新藥的優點。
  • 患者的愛好
    • 處方決策中患者選擇的重要性。投藥途徑、治療的頻率患者購買和醫療成本管理上的重要因素。
  • 下一代的展望
    • Anti-LINGO成為下個改變遊戲規則者的理由
  • 未支援患者層
    • 在RRMS治療上有許多選項,不過,進行性仍殘留未滿足需求的理由為何?新的治療藥發揮的作用為何?
  • 聯合治療
    • 多發性硬化症治療藥很多是單劑療法,成本成為聯合治療的抑制因素。創新的藥價設定將成為市場機會嗎?臨床上的優點可使成本正當化嗎?
  • 研究的方向性
    • 最近的臨床試驗相關KOL的見解

調查對象

  • 已上市藥物
    • Interferons (Avonex, Rebif, Betaseron, Extavia)
    • Plegridy (peginterferon beta-1a/BIIB017; Biogen)
    • Copaxone (glatiramer acetate; Teva)
    • Tecfidera (dimethyl fumarate; Biogen)
    • Aubagio (teriflunomide; Sanofi/Genzyme)
    • Gilenya (fingolimod; Novartis/田邊三菱製藥)
    • Tysabri (natalizumab; Biogen)
    • Lemtrada (alemtuzumab; Sanofi/Genzyme/Bayer HealthCare)
  • 開發平台藥物
    • Zinbryta (daclizumab high-yield process, DAC-HYP; Biogen/AbbVie)
    • Nerventra (laquinimod; Active Biotech/Teva)
    • Ozanimod (RPC 1063; elgene)
    • Siponimod (BAF 312; Novartis)
    • Ponesimod (ACT 128800; Actelion)
    • Ocrelizumab (Roche/Biogen)
    • Masitinib (AB 1010; AB Science)
    • Biotin (MD 1003; MedDay)
目錄
Product Code: 596200415

Roche's/Biogen's novel ocrelizumab is set to radically alter the Multiple Sclerosis (MS) treatment paradigm. Which companies and products will lose market share as its use widens and what clinical benefits underpin KOL excitement? Could it challenge interferon therapy? Where will oral therapies such as Novartis' Gilenya (fingolimond) fit in? Where will Biogen's well regarded Tecfidera (dimethyl fumarate) find a role?

This report reveals the unique insights of 12 leading US and European KOLs . How they view the clinical benefits of current and late-stage disease-modifying agents, safety concerns and the influence patients exert are fully explored. The report analyses 8 leading launched products and 8 significant late-stage therapies

"Ocrelizumab is the most exciting of all the MS drugs. This drug will take markets. This will be the most disruptive therapy of any therapy we've discussed." EU KOL

Answering key questions:

  • Ocrelizuzimab : What safety and dosage benefits underpin KOLs positive opinions about ocrelizumab?
  • Copaxone/Glatopa : Will longer acting formulations help Teva defend Copaxone revenues against Sandoz/Momenta's Glatopa (generic glatiramer acetate)?
  • Gilenya/Tecfidera : Have safety concerns blunted the growth of Novartis'Gilenya (fingolimond) and Biogen's Tecfidera (dimethyl fumarate) - how do KOLs see their role in the treatment paradigm evolving?
  • Plegridy : How is the launch of Plegridy impacting other interferon products and what effect will this have on the interferon market as a whole?
  • Lemtrada : How might the CAM-THY, EMERALD and TOPAZ trials for Sanofi's/Genzyme's Lemtrada (alemtuzumab) influence KOLs views?
  • Ozanimod/siponimod : Can new sphingosine modulators such as Celgene's ozanimod, Novartis' siponimod and Actelion's ponesimod differentiate themselves against established therapies and find a market?
  • Biotin : MedDay's ultra-high dose biotin (MD 1003) is showing promise for progressive diease and could be an effective low-cost treatment - but what KOL concerns do MedDay have to address in clinical trials?

Top Takeaways

  • A changing treatment paradigm : While ocrelizumab will initially compete as a second line in RRMS it could move to first line therapy and get traction in PPMS. Understand its clinical benefits and why it is being seen as a really potent alternative to current products.
  • A question of safety : Many treatments are effective in treating MS but come with a range of adverse reactions. Assess the impact safety is having on prescribing habits and how new therapies will benefit.
  • Patient preferences : Appreciate how patient choice plays a key role in prescribing decisions. The route of administration and frequency of treatment are critical to patient buy-in and healthcare cost control.
  • The next generation : Understand why Anti-LINGO could be the next game changer in multiple sclerosis.
  • Underserved patient populations : While there are plenty of options for the treatment of RRMS , there remains an unmet need for progressive forms of the disease - how will new treatments play a role?
  • Combination Therapy : Most MS treatments are given as monotherapy, and cost is cited as the dampener of combination treatment. Could innovative pricing be an opportunity area and would the clinical benefits justify the increase?
  • Research points the way : Review KOL attitudes to recently completed or ongoing clinical trials such as BEST-MS, CAM-THY, ORATORIO, OPTIMUM, ARPEGGIO and EXPAND.

Key Issues Explored

  • Patients play a critical role in therapy choice. The frequency of treatment, additional monitoring and fear of adverse reactions are just some of the issues that clinicians take into account. It's more than just efficacy and there are lessons for companies for their patient outreach programmes.
  • There is much promise in the new therapies coming to market but they are competing with established products whose profile and risks are known - it will take some time to build clinical confidence and start to fully realise their potential - medical and patient education will play a key role.
  • Product differentiation is critical in getting formulary placement. Knowing what product attributes and patient characteristics KOLs think are the most important in terms of prescribing decisions are "must-know" to ensure commercial success.
  • Unlike many treatment areas, combination therapy is not common in MS. KOLs cite cost as an issue, but could progressive pricing and combination therapy be considered as an end game for products superseded by new therapies?
  • How do KOLs view high-dose biotin (MD 1003) and what specific advantages would such a product have?

A report based on expert knowledge

US KOLs

  • Dr Robert Naismith, MD , Associate Professor of Neurology and Neurology Clerkship Director at Washington University in St. Louis
  • Dr Benjamin M. Greenberg, MD , Associate Professor and the Cain Denius Scholar in Mobility Disorders in the Department of Neurology and Neurotherapeutics at UT Southwestern Medical Center
  • Dr Daniel Harrison, MD , Assistant Professor of Neurology at Johns Hopkins University Medical Center and a faculty member of the Johns Hopkins MS Center
  • Dr Shiv Saidha, M.B.B.Ch , Assistant Professor of Neurology at Johns Hopkins University School of Medicine
  • Dr Darin T. Okuda, MD , Director of the Multiple Sclerosis and Neuroimmunology Imaging Program and the Deputy Director of the MS Program and Clinical Center for Multiple Sclerosis at the University of Texas Southwestern Medical Center in Dallas, Texas
  • Dr Anne Cross, MD , Professor of Neurology and Section Head of Neuroimmunology at Washington University School of Medicine, St. Louis

EU KOLs

  • Prof Cris Constantinescu , Head of the Academic Division of Clinical Neurology at the University of Nottingham; senior consultant in charge of the MS Clinic, University Hospital Nottingham
  • Prof Nighoghossian , Chief Neurologist at CHU Lyon, France
  • clinic in a university hospital.
  • Dr Elio Scarpini , Chief of the Center for Neurodegenerative and Demyelinating Disorders, University of Milan, Fondazione IRCCS Cà Granda, Ospedale Policlinico, Milan, Italy
  • Dr Belen Caminero , is responsible for the Multiple Sclerosis Unit in the Healthcare Complex of Avila, Spain.
  • Anonymous, German KOL , is a Professor of Neurology. This expert is Managing Lead Consultant of a neurology
  • Anonymous, European KOL , Principal investigator on several multinational MS clinical trials
  • Request Sample Pages

Get KOL insights on

Marketed MS Drugs

  • Interferons (Avonex, Rebif, Betaseron, Extavia)
  • Plegridy (peginterferon beta-1a/BIIB017; Biogen)
  • Copaxone (glatiramer acetate; Teva)
  • Tecfidera (dimethyl fumarate; Biogen)
  • Aubagio (teriflunomide; Sanofi/Genzyme)
  • Gilenya (fingolimod; Novartis/Mitsubishi Tanabe Pharma)
  • Tysabri (natalizumab; Biogen)
  • Lemtrada (alemtuzumab; Sanofi/Genzyme/Bayer HealthCare)

MS Pipeline

Zinbryta (daclizumab high-yield process, DAC-HYP; Biogen/AbbVie) Nerventra (laquinimod; Active Biotech/Teva) Ozanimod (RPC 1063; Celgene) Siponimod (BAF 312; Novartis) Ponesimod (ACT 128800; Actelion) Ocrelizumab (Roche/Biogen) Masitinib (AB 1010; AB Science) Biotin (MD 1003; MedDay)

WHO WINS AND WHO LOSES AS THIS HIGH GROWTH SECTOR PREPARES FOR ANOTHER TREATMENT REVOLUTION? ORDER YOUR COPY NOW FOR INSTANT DOWNLOAD

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, October.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.
Back to Top